Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16405431rdf:typepubmed:Citationlld:pubmed
pubmed-article:16405431lifeskim:mentionsumls-concept:C0014644lld:lifeskim
pubmed-article:16405431lifeskim:mentionsumls-concept:C0021051lld:lifeskim
pubmed-article:16405431lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:16405431lifeskim:mentionsumls-concept:C0079774lld:lifeskim
pubmed-article:16405431lifeskim:mentionsumls-concept:C0004083lld:lifeskim
pubmed-article:16405431lifeskim:mentionsumls-concept:C0022341lld:lifeskim
pubmed-article:16405431pubmed:issue2lld:pubmed
pubmed-article:16405431pubmed:dateCreated2006-1-12lld:pubmed
pubmed-article:16405431pubmed:abstractTextThe association of Epstein-Barr virus (EBV) with human immunodeficiency virus-negative T-cell lymphoma was examined in 68 patients using the polymerase chain reaction (PCR) with DNA obtained from formalin-fixed paraffin-embedded tissues and an in situ hybridization technique. EBV-encoded RNA (EBER) was detected in 43 of 68 cases (63%) of peripheral T-cell lymphoma: in 100% (11 of 11 cases) of NK/T-cell lymphomas, 70% (14 of 20 cases) of angioimmunoblastic T-cell lymphomas (AILT) and 49% (18 of 37 cases) of other types of peripheral T-cell lymphoma. A positive band was also detected at high incidence (36 of 65 cases; 55%) in a PCR analysis using primers to detect the Bam HI-W fragment of EBV. In the immunohistochemical analysis using a monoclonal antibody to latent membrane protein 1 (LMP-1) of EBV, one of the EBV-encoded latent gene products, LMP-1, was found to be expressed in 13 of 64 cases (20%), but EBNA-2 was not expressed in all the cases examined (0 of 59 cases; 0%). The 5-yr survival rate was 28% for peripheral T-cell lymphomas overall, 0% for NK/T-cell lymphomas, 38% for AILTs and 28% for other types of peripheral T-cell lymphoma. The difference in the overall survival rate between NK/T-cell lymphoma and non-NK/T-cell lymphoma was significant (P = 0.0498 by Log-rank test). Among peripheral T-cell lymphoma patients overall, the group severely infected with EBV (EBER-ISH ++) had a lower 5-yr survival rate (8%) than the group slightly (EBER-ISH +) or not infected (38%; P = 0.0013).lld:pubmed
pubmed-article:16405431pubmed:languageenglld:pubmed
pubmed-article:16405431pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16405431pubmed:citationSubsetIMlld:pubmed
pubmed-article:16405431pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16405431pubmed:statusMEDLINElld:pubmed
pubmed-article:16405431pubmed:monthFeblld:pubmed
pubmed-article:16405431pubmed:issn0902-4441lld:pubmed
pubmed-article:16405431pubmed:authorpubmed-author:UmeharaHisano...lld:pubmed
pubmed-article:16405431pubmed:authorpubmed-author:KawabataHiros...lld:pubmed
pubmed-article:16405431pubmed:authorpubmed-author:FukushimaTosh...lld:pubmed
pubmed-article:16405431pubmed:authorpubmed-author:HiroseYukoYlld:pubmed
pubmed-article:16405431pubmed:authorpubmed-author:MasakiYasufum...lld:pubmed
pubmed-article:16405431pubmed:authorpubmed-author:OgawaNoriyosh...lld:pubmed
pubmed-article:16405431pubmed:authorpubmed-author:WanoYujiYlld:pubmed
pubmed-article:16405431pubmed:authorpubmed-author:ShimoyamaKumi...lld:pubmed
pubmed-article:16405431pubmed:authorpubmed-author:KarasawaHirom...lld:pubmed
pubmed-article:16405431pubmed:authorpubmed-author:SawakiToshiok...lld:pubmed
pubmed-article:16405431pubmed:issnTypePrintlld:pubmed
pubmed-article:16405431pubmed:volume76lld:pubmed
pubmed-article:16405431pubmed:ownerNLMlld:pubmed
pubmed-article:16405431pubmed:authorsCompleteYlld:pubmed
pubmed-article:16405431pubmed:pagination109-18lld:pubmed
pubmed-article:16405431pubmed:meshHeadingpubmed-meshheading:16405431...lld:pubmed
pubmed-article:16405431pubmed:meshHeadingpubmed-meshheading:16405431...lld:pubmed
pubmed-article:16405431pubmed:meshHeadingpubmed-meshheading:16405431...lld:pubmed
pubmed-article:16405431pubmed:meshHeadingpubmed-meshheading:16405431...lld:pubmed
pubmed-article:16405431pubmed:meshHeadingpubmed-meshheading:16405431...lld:pubmed
pubmed-article:16405431pubmed:meshHeadingpubmed-meshheading:16405431...lld:pubmed
pubmed-article:16405431pubmed:meshHeadingpubmed-meshheading:16405431...lld:pubmed
pubmed-article:16405431pubmed:meshHeadingpubmed-meshheading:16405431...lld:pubmed
pubmed-article:16405431pubmed:meshHeadingpubmed-meshheading:16405431...lld:pubmed
pubmed-article:16405431pubmed:meshHeadingpubmed-meshheading:16405431...lld:pubmed
pubmed-article:16405431pubmed:meshHeadingpubmed-meshheading:16405431...lld:pubmed
pubmed-article:16405431pubmed:meshHeadingpubmed-meshheading:16405431...lld:pubmed
pubmed-article:16405431pubmed:meshHeadingpubmed-meshheading:16405431...lld:pubmed
pubmed-article:16405431pubmed:meshHeadingpubmed-meshheading:16405431...lld:pubmed
pubmed-article:16405431pubmed:meshHeadingpubmed-meshheading:16405431...lld:pubmed
pubmed-article:16405431pubmed:meshHeadingpubmed-meshheading:16405431...lld:pubmed
pubmed-article:16405431pubmed:year2006lld:pubmed
pubmed-article:16405431pubmed:articleTitleAssociation of Epstein-Barr virus with human immunodeficiency virus-negative peripheral T-cell lymphomas in Japan.lld:pubmed
pubmed-article:16405431pubmed:affiliationDepartment of Hematology and Immunology, Kanazawa Medical University, Ishikawa, Japan. y-hirose@kanazawa-med.ac.jplld:pubmed
pubmed-article:16405431pubmed:publicationTypeJournal Articlelld:pubmed